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ABSTRACT 
Complement (C) activation-related hypersensitivity reactions (HSRs) represent an unsolved adverse immune effect of 
many i.v. administered “nanomedicines”, such as liposomal doxorubicin (Doxil/Caelyx). Because these pseudoallergic 
reactions can be severe or even lethal, it is an important clinical objective to find biomarkers for proneness for C activa-
tion by reactogenic nanoparticles that will allow the prediction of in vivo reactions by in vitro assays. With this goal in 
mind we identified a normal human blood donor whose serum consistently showed high sensitivity to Caelyx-induced C 
activation in vitro (CSS). The plasma of this blood (Caelyx-sensitive plasma, CSP) was subjected to proteome profiling 
with a library of human plasma proteome specific mAbs. The chip (PlasmaScan-380TM) contained 380 non-redundant 
(with respect to epitopes) mAbs. The analysis revealed 8 proteins that were differentially represented in CSP in com-
parison with Caelyx-insensitive control plasma. These proteins were identified by mass spectrometry and Western blot 
analyses to represent factor H (decreased in CSP), factor H related protein, serum amyloid P component, fibronectin, 
complement component C4, Apo B100, prothrombin and alpha-2-HS glycoprotein (all increased in CSP). Some of these 
protein changes are consistent with proneness for increased C activation, suggesting the potential use of this method in 
the search for biomarkers for liposome-induced or other types of nanomedicine-induced HSRs. 
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1. Introduction 
Complement (C) activation-related pseudoallergy (CARPA) 
is a relatively new concept that explains those drug-in- 
duced acute hypersensitivity reactions (HSRs) where the 
drug activates C while a role for specific IgE, or direct 
stimulation of mast cells cannot be identified [1]. Lipo- 
somal drugs, such as liposomal doxorubicin (Doxil, 
Caelyx), micellar solvents, radiocontrast media, mono- 
clonal antibodies, enzymes and a variety of polymeric 
and miscellaneous other types of drugs can cause such 
reactions, also known as infusion or anaphylactoid reac- 
tions [1,2]. The clinical picture includes typical allergic 
symptoms with skin rash and signs of cardiopulmonary 
distress, and shows substantial individual variation. While 
tolerable in most cases, the main problem with CARPA 
is that it can be fatal in an occasional hypersensitive in- 
dividual; however, there is at present no known diagnos- 
tic method to predict who will react [3-5]. Thus, severe 
CARPA represents a life-threatening condition whose 
prevention could be significantly advanced by develop- 
ing a predictive laboratory assay [2]. 
With this ultimate goal in mind, the present prelimi- 
nary study was initiated to utilize a new, state-of-the-art 
protein biomarker profiling method to identify biomarker 
candidates for CARPA. Monoclonal antibody proteomics, 
the methodology applied in the work, has recently shown *Corresponding author. 
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unique success in identifying lung cancer specific [6,7] 
and other biomarkers [8] using high throughput ELISA 
assays for the discovery. In this study, to further explore 
the potential of mAb proteomics technology, an antibody 
biochip (PlasmaScan-380TM) on which 380 monoclonal 
antibodies (mAb) are coated with specificity for native, 
immunogenic, accessible epitopes present in human plas- 
ma was applied for biomarker research. 
Our working hypothesis was that using the PlasmaS- 
can-380TM biochip for comparative protein profiling of 
normal human plasmas and a human plasma which shows 
increased sensitivity to Caelyx-induced C activition would 
reveal differences in one or more protein levels that might 
serve as biomarker candidates for proneness for C ac- 
tivation, and, hence CARPA. 
2. Materials and Methods 
2.1. Materials 
Caelyx®, the trade name of Doxil® in Europe, was ob- 
tained from the pharmacy of Semmelweis University. It 
contains doxorubicin, 2 mg/mL (4.22 mM); fully hydro- 
genated soy phosphatidylcholine (HSPC), 9.58 mg/mL; 
cholesterol (Chol), 3.19 mg/mL; 2K-PEG-DSPE (N-car- 
bamyl-poly(ethylene glycol methyl ether)-1, 2-distea- 
royl-sn-glycerol-3-phosphoethanolamine triethyl ammo-
nium salt with a polyethylene glycol (PEG) moiety of 
average molecular mass of 2000 Da, 3.19 mg/mL; am- 
monium sulfate, ~0.2 mg/mL; histidine (10 mM, pH 6.5); 
and sucrose (10%). Total phospholipid: 12.8 mg/mL (13.3 
mM). Zymosan A was purchased from Sigma-Aldrich 
Hungary Ltd. PlasmaScan-380TM biochips were provided 
by ArrayIt Co’s (http://arrayit.com/),  
(http://arrayit.com/Products/Protein_Microarrays/Plasma
Scan_Microarrays/plasmascan_microarrays.html). Normal 
pooled human plasma was purchased from the Institute 
Nationale de la Transfusion Sanguine (INTS, France). 
2.2. Methods 
2.2.1. Preparation of Normal Human Plasma  
and Serum 
Human blood was drawn from healthy volunteers by ve- 
nipuncture according to an institutionally approved pro-
tocol. The blood was then either anticoagulated with 
EDTA, or allowed to clot at room temperature, followed 
by centrifugation at 3500 g for 7 min. The supernatant 
sera (normal human serum, NHS) were used either 
freshly, or were aliquoted and stored at −80˚C. Frozen 
specimens were thawed at 37˚C and kept on ice until use. 
2.2.2. Measurement of Complement Activation 
The serum specimens were exposed to Doxil at the vol-
ume ratio of 3:1; typically, 15 μl of serum was mixed 
with 5 μl of 10-fold diluted Doxil in Eppendorf tubes, 
which were then incubated at 37˚C for 60 min. Samples 
were placed on ice, and C reactions were stopped by 980 
μl of specimen diluents, provided by the supplier, com-
pleted with 10 mM EDTA. Reaction markers of C acti-
vation were quantitated by enzyme-linked immunosor-
bent assays (ELISA). The reagent kits for SC5b-9, 
C3a-desArg and Bb were purchased from Quidel Ltd (via 
TECO-Medical Group, Sissach, Switzerland), while the 
C5a-desArg test was supplied by BD Biosciences Inc. 
Absorbance values at 450 nm were measured by a Flu-
oStar Omega microplate reader. Concentration of ana-
lytes was determined in the linear range of the calibration 
curves. 
2.2.3. Statistical Analysis of Complement Activation  
Data 
Kolmogorov-Smirnov test was conducted to evaluate the 
normality assumption of the data sets. To assess statisti- 
cal significance, one-way ANOVA followed by Dun- 
nett’s post-hoc evaluation, was used. The difference be- 
tween two groups was considered statistically significant 
at p < 0.05. A test material induced C activation, when 
parallel treatments of a randomly selected group of sera 
resulted in a significant increase of a C activation product, 
relative to the vehicle controls. 
2.2.4. Preparation of Plasma for Biochip Analysis 
EDTA-anticoagulated plasma from the same patients, 
whose sera was analyzed for C activation (see above), 
were subjected to biochip analysis as follows. The seven 
most abundant plasma proteins were depleted from the 
sera in an AKTA purifier-10 HPLC workstation (GE 
Healthcare Ltd. Piscataway NJ USA) using the Human-7 
Multiple Affinity Removal System (MARS) (Agilent 
Technologies, Santa Clara, CA). The individual depleted 
plasma samples were labeled with a bi-functional NHS- 
biotin having a long alkyl chain as a spacer EZ-Link 
Sulfo-NHS-LC-Biotin from Pierce (Rockford, IL) accor- 
ding to the manufacturer’s instructions. Protein concen- 
tration of the samples was then determined by the BCA- 
method and was set to either 5 or 10 mg/ml, working 
aliquots were stored at −70˚C. 
2.2.5. Characteristics and Use of PlasmaScan-380TM  
Biochips 
PlasmaScan-380TM biochips have been printed on a mi-
croscope slide-sized glass plate (six/plates), each con-
taining 380 different antibodies spotted in triplicates. The 
microarrays were activated for 60 min by the protein 
microarray activation buffer, and the chips were washed 
two times for 5 min in protein microarray wash buffer 
and one time for 1 sec in protein microarray rinse buffer. 
After washing, they were dried by spinning for 1 sec in a 
microarray high-speed centrifuge. Samples for microar- 
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ray analysis were prepared by mixing 50 µg (5 to 10 µl) of 
labeled serum proteins with protein microarray reaction 
buffer. The same volume of protein sample was used for 
all reactions. Activated PlasmaScan™ microarrays were 
reacted with labeled plasma samples in an AHC1 × 24 or 
AHC4 × 24 microarray hybridization cassette with a 
modified gasket having 300 µl reaction volumes. The 
binding was allowed to proceed for 60 min at room tem- 
perature with gentle mixing. The reaction was stopped by 
washing the microarrays three times for 3 min in protein 
microarray wash buffer, with gentle agitation. After wa- 
shing, the slides were dried by spinning for 1 sec in a 
microarray high-speed centrifuge. 
2.2.6. Visualization of Bound Proteins 
To visualize antibody-bound proteins, the microarrays 
were stained with a fluorescent (Cy3™) streptavidin se- 
condary reagent, diluted to 1 µg/ml in protein microarray 
reaction buffer. Staining was done for 60 min at room 
temperature with gentle agitation. Microarrays were wa- 
shed three times for 3 min in protein microarray wash 
buffer and one time for 1 sec in protein microarray rinse 
buffer with gentle agitation. After washing chips were dried 
as above. Finally, the microarrays were scanned for fluo-
rescence emission using Arrayit InnoScan® 710 (is710 
70LC1 709045) microarray scanner. Scanner settings were: 
pixel size: 5 µm, scanning wavelength: 635 nm.  
2.2.7. Biochip Image Analysis and Quantitation 
All data files were saved as 16-bit TIFF images for data 
analysis. Spot intensities in these images were quantified 
using Arrayit Mapix Microarray Quantification Software 
(Mapix 4.6.2, driver 5.0.0) and data were saved in a 
text-file (.txt). The .txt file was imported into Microsoft 
Excel for additional analysis. As a first step, median 
background subtracted spot pixel intensities were thre- 
shold corrected. Threshold was calculated using the equ- 
ation: [3 × B × CVb,] where B equaled to the median 
local background of each spot and CVb expressed the 
averaged coefficient of variation of all the backgrounds 
on the array. Those (“bad”) spots, of which median 
background subtracted spot pixel intensity was lower 
than the threshold were not used in further calculations. 
Replicates were combined; means and standard deviations 
(SD) were calculated in each array. When the standard 
deviation within the replicates was larger than 1/3rd of the 
mean [SD > (mean/3)] the outlier spot was identified and 
its value was eliminated. 
For global normalization, the sum of total intensities of 
all spots within each array was calculated. Within the 
corresponding replicate arrays, a correction factor (cf) 
was determined. For example, correction factor between 
array A and B (cfAB) is calculated from the total intensity 
of array *A (TIA) divided by the total intensity of array 
*B (TIB): cfAB = TIA/TIB. Using the correction factor 
the median background subtracted intensity of each spots 
was recalculated: TIB × cfAB. Scatter plots of raw and 
global normalized data and selection of differentiating 
antibodies were done using the selected data pairs. To 
select antibodies giving significant signals (higher than 
sample signal deviation), global mean normalizations 
were done to correct systematic bias in antibody signal 
ratios by fitting the LOESS regression in R software [9]. 
In the next step, the residuals (distances between the 
original points and the LOESS regression derived values 
at the given x axis position) were calculated and plotted 
as corrected ratio. Finally antibodies giving significantly 
different signals, with values higher or lower than ± 2 × 
SD (standard deviation calculated from the corrected 
ratios) were recorded. 
The analysis was done for each of three individual ex- 
periments separately, and the antibodies that were re- 
corded in at least two separate experiments were selected 
for antigen specificity determination. 
2.2.8. Determination of the Antigen Specificity of 
Selected Antibodies 
2.2.8.1. Immunoprecipitation 
The antigen was first immuno-precipitated with the se-
lected antibodies using the Dynabeads protein G im-
muno-precipitation kit (Invitrogen, San Diego, CA). All 
steps were carried out using the buffers and instructions 
supplied by the manufacturer. Briefly, immunoaffinity 
magnetic beads were prepared for each selected antibody 
individually by mixing the antibody with protein G cou-
pled dynabeads followed by covalent cross-linking of the 
bound antibody using dimethoxypropane (DMP). The 
antigen was immune-precipitated by mixing the immu-
noaffinity beads with IgG depleted total human plasma, 
and if this immuno-precipitation was not successful, then 
it was done with the seven most abundant protein de-
pleted human plasma (Human-7 Multiple Affinity Re-
moval System (MARS) from Agilent Technologies (San- 
ta Clara, CA)) to increase the chance of the antibody to 
find its antigen. Following incubation to allow antigen 
binding, the beads with bound antigen were washed and 
the antigen eluted using elution buffer supplied with the 
kit. Proteins from the resulting eluate were separated by 
SDS-PAGE and the gels subjected to coomassie blue or 
silver staining. 
2.2.8.2. Mass-Spectrometry Analysis 
2.2.8.2.1. In-Gel Digestion 
The band(s) corresponding to the specifically immuno- 
precipitated protein was excised, subjected to in-gel tryp- 
sin digestion and the samples processed for mass-spec- 
trometry analysis. The latter was performed at the Labo- 
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ratory of Proteomics Research at the Biological Research 
Center of the Hungarian Academy of Sciences (Szeged, 
Hungary) using a Thermo LCQ Fleet 3D ion trap coupled 
with Eldex nano-HPLC system. Data were analyzed us-
ing Mascot software with default parameters and the 
searches were restricted to human sequences. 
2.2.8.2.2. In Solution Digestion 
The specifically immune-precipitated proteins were sub-  
jected to in-solution trypsin digestion according to a pre- 
viously described protocol [10] at the Institute of Struc- 
tural Chemistry at the Chemical Research Center of the 
Hungarian Academy of Sciences (Budapest, Hungary). 
The samples were processed for mass-spectrometry (MS) 
analysis using a QTOF Premier mass spectrometer (Wa- 
ters, Milford, MA, USA) coupled with a nanoflow 
UHPLC system (nanoAcquity UPLC, Waters, Milford, 
MA, USA). MS survey data was processed using Pro- 
teinLynx Global Server v.2.3 (Waters, Milford, MA, 
USA) and searched against version 2011_10 of Swiss- 
Prot sequence database using Mascot Server version 2.2 
(Matrix Science, London, UK). One missed cleavage was 
allowed, carbamidomethyl cysteine was set as fixed mo- 
dification and the searches were restricted to human se- 
quences. 
2.2.8.3. Western Blot (WB) Analysis 
Ten μg of human total and MARS-depleted plasma pro- 
tein samples were separated by SDS-PAGE on 4% - 20% 
Tris-Glycine gel from Invitrogen (San Diego, CA) under 
reduced as well as non-reduced conditions, and transferred 
to a 0.45 μm nitrocellulose membrane (Whatman) by 
electroblotting. Membranes were blocked for 1 hour in 
PBS-Tween (pH 7.2) containing 5 mg/ml Polyvinylpyr- 
rolidone (Sigma) and incubated individually with the 
specific monoclonal antibodies selected from the chip ex- 
periments (0.2 or 0.4 µg/ml) overnight. Immunoblots 
were developed by peroxidase-conjugated anti-mouse 
antibody from Southern Biotechnology Associates, Inc. 
(Birmingham, AL) and an ECL detection kit (Pierce 
(Rockford, IL). Protein bands were detected using dif- 
ferent exposure times with a Gel Logic 1500 imaging 
system and Kodak MI software from Eastman Kodak 
(Rochester, NY). PageRuler Prestained Protein Ladder 
(Fermentas, Thermo Fischer Scientific) and MagicMarkXP 
Western Protein ladder (Invitrogen) were used for mo- 
lecular weight determination. 
2.2.9. ELISA with Commercial Purified Proteins 
Ninetysix well plates (Corning 96 well plates, half-area 
clear polystyrene, high-binding, non-sterile, Sigma) were 
coated with 30 µl/well of a serial concentration (from 2 
µg/ml to 15 µg/ml) of commercial purified proteins at 
37˚C for 60 minutes. 
Protein was prepared in carbonate coating buffer (15 
mM Na2CO3, 35 mM NaHCO3, pH 9.6) or PBS (123 mM 
NaCl, 3 mM KH2PO4, 10.5 mM Na2HPO4, pH 7.2) for 
coating depending on its isoelectric point. After washing 
the plates for 2 times with PBS-Tween buffer (PBS and 
0.5 v/v% Tween-20, pH 7.2) wells were blocked at 37˚C 
for 30 minutes in 60 µl/well of blocking buffer (500 mM 
NaCl, 3 mM KH2PO4, 10.5 mM Na2HPO4, 0.5 v/v% 
Tween-20, 0.5 m/m % bovine serum albumin, pH 7.2). 
After 3 times washing, plates were incubated with serial 
dilutions of mouse monoclonal antibodies at 37˚C for 60 
minutes. All antibody dilutions were done in blocking 
buffer. Antigen captured antibodies were detected with 
HRP labeled polyclonal goat anti mouse IgG, Human Ad-
sorbed (GAM-HRP; Southern Biotech, Birmingham, AL, 
USA) secondary antibody diluted to 1:8000 utilizing TMB 
(3,3’,5,5’,-tetramethylbenzidine; Sigma). The co-lorimet- 
ric reactions were stopped with 30 µl/well of 4n H2SO4, 
then endpoint measurements were done at 450 nm. 
Raw data were imported into Office Excel software for 
further data manipulations such as background (incu- 
bated with blocking buffer instead of plasma samples) 
correction and plotting. 
3. Results 
3.1. Selection and Tests on Caelyx Sensitive Serum 
Previous studies showed substantial individual and inter- 
experimental variation of C activation by Doxil in NHS 
in vitro [11,12], highlighting the sensitivity of the assay 
to individual controlling factors and experimental condi- 
tions. This variation necessitated that for our predictive 
biomarker identification we use serum wherein, under 
our experimental conditions, Caelyx exerts strong and 
consistent C activation in comparison with serum where- 
in the drug is not reactive. 
Figure 1 shows the experiments which ensured the 
presence of these preconditions: in Figure 1(a) we incu- 
bated Caelyx with 10 different NHS and found in one 
relatively high (3-fold, or 200%) rise of SC5b-9 (Figure 
1(a)), arrow), indicating relatively “strong” C activation. 
The rise of SC5b-9 in this Caelyx sensitive serum (CSS) 
was quantitatively reproduced in 4 independent experi- 
ments on different days using the CSS collected at dif-
ferent occasions from the same donor (Figure 1(b)), su- 
ggesting that the increased reactivity was an inherent 
feature of this CSS. 
Figure 2 shows that the above described elevation of 
SC5b-9 in CSS was a manifestation of activation of the 
whole C cascade, inasmuch as it was associated with ele-
vation of C3a (Figure 2(a)) and C5a (Figure 2(b)), i.e., 
anaphylatoxins which mediate the clinical symptoms of 
CARPA. Thus, it could be excluded that the Caelyx-in- 
duced rise of SC5b-9 was an isolated protein response in 
SS. Finally, Figure 2(c) shows that Caelyx caused eleva-  C  
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Figure 1. Complement activation by Caelyx in normal human sera, measured by ELISA of SC5b-9 production after 60 min 
incubation at 37˚C. (a) Measurements done in 10 NHS, Zymosan was used as a positive control at 300 µg/mL final 
concentration. (b) Four independent experiments as in (a), using the serum which in (a) showed sensitivity to Caelyx (arrow). 
Serum samples were stored at −80˚C until complement activation and ELISA. Significant differences were established by one 
way ANOVA (***p < 0.001, **p < 0.01, *p < 0.05). 
 
  
(c) (a) 
Figure 2. Effect of Caelyx on C3a (a), C5a (b) and Bb (c) 
formation in the CSS identified in Figure 1(a). Serum sam- 
ples of the Caelyx-reactive donor were treated by Caelyx 
or zymosan A (300 µg/mL) for 60 min at 37˚C. Bars 
indicate mean ± SEM of two data points per column. 
Significant differences were calculated by one way ANOVA 
(**p < 0.01). 
 
 
tion of Bb in CSS, providing evidence for the involvement 
of the alternative pathway in the C activation. 
3.1.1. Quality Controlling of Biochip Studies 
Two critical parameters characterizing the function of 
biochips are the number of outliers (SD > Mean/3) and 
bad spots (threshold > intensity). In our 3 different bio- (b) 
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chip screenings in this study, both the number of bad 
spots and the outliers remained below 7%. Their appearance 
did not show any pattern, however, there were some 
antibodies where irregularities occurred more frequently 
than with others. As the antibodies were spotted in each 
array in triplicates, the presence of one outlier or one bad 
spot in one triplicate did not have significant effect on 
the results. However, if in case of one triplicate two spots 
were bad or outlier, this antibody was not considered in 
the analysis. The average percent of antibodies that must 
have been left out from the evaluation in one of the 
screenings was 8.5%, 1.2% of them had to be left out 
twice and less than 0.2% of them had to be left out in all 
three experiments.  
3.1.2. Selection of Differentiating Antibodies 
Differentiating antibodies were selected as described 
above. The residuals (differences between the LOESS 
regression derived and the original ratio values) were 
plotted as a function of average signal intensity of the 
two samples for each antibody. Antibodies giving sig- 
nificantly different signals, with values higher or lower 
than ± 2 × SD (standard deviation calculated from the 
corrected ratios) were recorded. Figure 3 shows part of 
one analysis of an experiment when all the antibodies are 
displayed on the graph and the differentiating ones are 
listed on the side table. The cognate antigen of 8 anti- 
bodies appeared in higher and of 9 antibodies in lower 
amount in CSS than in the Caelyx insensitive sera. Out of 
these antibodies, four (Bsi0296, Bsi0790, Bsi1547 and 
Bsi1328) were selected later as hits. 
3.1.3. Determination of Cognate Antigens of the  
Selected Antibodies 
Antigen specificity of the selected antibodies was deter- 
mined by MS analysis of the immunoprecipitates and 
results were verified by WB and EIA, using commercially 
available standard proteins. Immunoprecipitates were 
separated on SDS-PAGE and bands containing the 
suspected specific proteins were cut out and subjected to 
MS analysis (in-gel digestion). When it was difficult or 
was not possible to determine and pick the specific bands 
after the SDS-PAGE separation, the whole immunpre- 
cipitate was analyzed by MS (in solution digestion). By 
way of an example, Figure 4 shows the detailed results 
for Bsi1547. Here, after immunoprecipitation, a single 
band of >70 kDa appeared (panel A) also the WB 
showed the specific recognition of a protein of >70 kDa, 
the concentration of which increased in the plasma 
sample after depletion of the seven most abundant pro- 
tein. It was also evident that the antibody recognized 
only the non-reduced form of the protein, indicating the 
presence of a structured epitope stabilized by probably 
several disulphide bonds (Figure 4(b)). MS analysis of  
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Figure 4. Identification and validation of the cognate anti- 
gen for the monoclonal antibody Bsi1547. (a) Analysis of 
immunoprecipitate by SDS-PAGE (reduced) followed by 
Coomassie BB staining: lane 1, immunoprecipitate; lane 2, 
standard for molecular mass calculation PageRuler Pre- 
stained Protein Ladder (Fermentas); (b) Western Blot of 
different plasma samples: 5 µg each of total (lanes 1, 3) and 
Hu7 depleted healthy (lanes 2, 4) human plasma samples 
separated under reduced (1, 2) and non-reduced (3, 4) were 
probed with Bsi1547 mAb and was developed by ECL. 
Lane 5 is the Mw markers (Prosieve QuadColor Protein 
Markers (Lonza)) stained with amidoblack on the mem- 
brane. (c) Binding of antibodies to human prothrombin 
(Sigma) in an indirect EIA. Bsi0365 (human protrombin 
specifikus mAb); Bsi0185 (isotype matched monoclonal an- 
tibody with irrelevant specificity). 
 
the sample showed the presence of several, most likely 
associated proteins (Table 1)α-2-macroglobulin, pro- 
thrombin and complement C3 almost equally represented 
by the number of identified peptides. From these proteins 
the molecular weight of protrombin was closest to the 
size of that of the polypeptide shown up on the gels 
orrecognized on NC membrane; therefore its identity was 
verified with an ELISA assay using commercial proteins. 
r m Figure 4(c) it is evident that Bsi1547 recognized  F o    
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Table 1. Proteins identified from Hu7-depleted plasma immunoprecipitate of Bsi1547 antibody. 
Pr
D  MW 
otein Coverage Peptides Mascot Score escription
Alpha 2 m 1acroglobulin 21.44 25 946.14 63,187 
Prothrombin 38.42 25 907.53 69,992 
Complement C3 
 C5 
 
ubcomponent 
18.52 24 768.47 187,029 
Vitronectin 21.34 10 388.34 54,271 
Complement 6.74 11 341.88 188,185 
Complement C4 A 5.10 7 229.44 192,649 
Complement C1q s
subunit B 
Complement C1q subcomponent 
23.72 5 232.46 26,704 
subunit C 22.04 5 356.94 25,757 
 
Table 2. Summary of the identified antigens for the selected antibodies with MS-data. 
ascot search) MS data(M
Antibody Antigen mixture Sample digestion Identified Antigen antigen ID Numbe Score 
ence 
for MS r of 
Sequ
peptides coverage (%) 
Bsi0269 Hu7 dhp in gel Fibronectin gi|53791223 1389 30 18 
Bsi0790 Hu7 dhp in solution Co A 
C  
Bsi0893 Hu7 dhp in gel 
g  
Bsi1046 IgG dhp in gel 
in solution Apo
A g
in solution 
mplement C4 gi|50242 55 2401 29 
omplement Factor H gi|31965 36 1501 37 
Complement Factor H 
Related Protein 1 
Serum amyloid P  
component 
i|11844283 12 712 36 
gi|576259 15 986 42 
Bsi1307 Hu7 dhp lipoprotein B100 gi|4502153 54 2088 14 
Bsi1328 Hu7 dhp in gel Complement Factor H gi|31965 37 1134 34 
Bsi1448 Hu7 dhp in gel lpha-2-HS-glycoprotein i|2521983 5 262 18 
Bsi1547 Hu7 dhp Prothrombin gi|558069 25 907 38 
dh ed hum  
 
l as the control prothrombin spe- 
ve vs. Non-Reactive  
e 
4. Discussion 
pects 
-
AID sarcoma, and later, for ovarian 
il in up to 10% of 
cancer patients [21], which, based on publicly available    
p = deplet an plasma.
prothrombin just as wel
cific monoclonal antibody. 
With similar procedures all the eight antigens for 
the antibodies were determined, the summary of the 
MS data are shown in Table 2. 
3.1.4. Protein Differences in Reacti
Plasma 
Table 3 shows the changes in the representation of th
proteins, whose levels were found to be significantly 
different in CSP relative to one or two out of 3 control 
non-sensitive plasma samples with spot intensities being 
higher in sensitive compared to non-sensitive plasma in 
the case of 7 proteins, and lower in the case of one 
protein (Table 3). In 2 cases (fH and SAP), the changes 
were consistent with what is known about the impact of 
these proteins on C activation, as detailed in the dis- 
cussion below. 
4.1. Hypersensitivity to Liposomal Doxorubicin:  
Clinical As
Liposomal doxorubicin (Doxil/Caelyx) is the first “nano  
drug” approved by the FDA [13] initially (in 1995) for 
S-related Kaposi’s 
cancer and myeloma multiplex. Its use in cancer che-
motherapy has been rising over the years, and, as 
shown by the high number (~400) of completed or on-
going clinical trials testing its single or combination 
use in various cancers [14], its clinical application is 
expected to further rise in the future. 
Hypersensitivity, or infusion reaction to Doxil is one 
of the early recognized [15-20], yet until today unsolved 
adverse immune effect of this drug. Most recent statistics 
specify the occurrence of HSR to Dox
Copyright © 2013 SciRes.                                                                                 ANP 
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yx s
aelyx sensitive vs. Caelyx insensitive plasmas 
 
Table 3. Protein representation changes in Cael ensitive relative to Caelyx insensitive plasmas. 
Protein Direction of change Fold change: C
fH 05 down −1.89 ± 0.03 −2.25 ± 0.68 −1.08 ± 0.
fH and fHR 3.
m Amyloid P 
glycoprotein 
P up 42 ± 0.41 1.88 ± 1.35 1.13 ± 0.71 
Seru up 4.40 ± 1.33 1.78 ± 1.59 7.53 ± 5.97 
Fibronectin up 1.37 ± 0.48 3.23 ± 0.75 1.35 ± 0.61 
Apolipoprotein B100 up 1.33 ± 0.12 1.35 ± 0.15 1.66 ± 0.38 
Alpha-2-HS- up 1.66 ± 0.45 2.21 ± 1.98 2.54 ± 1.62 
C4A up 1.90 ± 0.45 1.47 ± 1.05 0.86 ± 0.44 
Protrombin up 1.49 ± 1.09 2.37 ± 1.10 1.01 ± 0.89 
V  the table show the averaged global normal ntensity ratio of the di amples (mean  entries are r rre-
spo als were higher than 2 × of SD of the ted residual mean. T s the monoclona rray-bound labe  whose 
ra  normalized pixel intensities were significantly lower (down) o ) than those in aelyx insensi mples. 
These proteins repeatedly showed statistically significant deviation from the microarray’s inherent variations in at least two out of 3 similar hybridizations. 
metimes fatal allergic/anaphylactoid-like infusion reac- 
 
 the 
capab  cause C activation. Hence, the 
hich ratio, by and 
large corresponds to the ratio of HSRs to Doxil (10%). 
inter-experi- 
m
4.
 able to recognize accessi- 
 
lation ry the imprints of their also 
alues in ized i fferent plasma s  ± SD). Bolded atios when the co
nding residu
w and globally
 calcula he table show
r higher (“up”
l antibody a
 (3 different) C
led proteins,
tive plasma sa
Their identities were determined via immunoprecipitation using dynabeads, followed by MS and Western blot analyses, as described. 
 
drug cost and sale figures, projects the number of re- 
actions in a year roughly in the 104th order. Serious and 
The experiment serving this goal, i.e., incubation of 
Caelyx with 10 NHS showed 1 CSS, w
so
tions have also been reported [21], which unfortunate 
facts highlight the clinical significance of a predictive 
laboratory test that may eliminate this risk. 
4.2. The Role of Complement Activation: The  
CARPA Concept 
Hypersensitivity reactions to Doxil and other liposomes
were previously shown to arise, at least in part, from
ility of liposomes to
phenomenon was called C activation-related pseudoallergy 
(CARPA) [5,11,16,22-24]. An early clinical study ana- 
lyzing the correlation between C activation in vivo and 
rise of clinical symptoms in cancer patients treated with 
Doxil for the first time established that the plasma levels 
of SC5b-9 (S-protein-bound C terminal complex), a mar- 
ker of C activation, correlate with the presence and se- 
verity of symptoms only in case of “strong” C acti- 
vation, roughly defined as several-fold rise of SC5b-9 
over baseline [16]. It follows from this observation that C 
activation may be a contributing factor to HSRs, a co- 
trigger, only above certain threshold level of activation. 
Consequently, only those people may be susceptible to 
CARPA in whom Doxil/Caelyx activates C above this 
threshold. Hence, a search for (a) biomarker (s) needed to 
be done in blood wherein Doxil/Caelyx activates C to the 
above defined degree. Accordingly, the first goal of this 
study that we had to reach was to identify a human blood 
donor in whose serum Caelyx caused C activation re- 
sulting several-fold increase of SC5b-9, which we re- 
ferred to as Caelyx-sensitive serum (CSS). 
Nevertheless it needs to be pointed out that the ratio of 
Doxil reactive sera and extent of C activation by Doxil in 
different human sera shows substantial 
ental variation in vitro as the source and age of lipo- 
somal doxorubicin [11,12], possible presence of aggre- 
gates [25] and the treatment of blood and sera can all 
influence the results, just as the incubation conditions. 
During the experiment presented here special attention 
was paid to storage of sera and plasma at -80˚C, thawing 
sera at 37˚C for C activation assays and aliquoting and 
diluting Caelyx under sterile conditions. 
After finding a CSS as detailed above, we set out to 
pursue the original, “innovative” research for finding 
biomarkers of extensive C activation in the plasma of this 
CSS donor, by applying monoclonal antibody proteomics 
on the plasma of this donor. 
3. Plasma Proteome Profiling with Monoclonal  
Antibody Libraries 
Biosystems International’s monoclonal antibodies are 
made against mixtures of native human plasma proteins 
therefore these antibodies are
ble epitopes on these polypeptides. Proteins in their na- 
tive configuration, harbor numerous potential post-trans-
al modifications and car
numerous interactions with other (macro) molecules in- 
cluding other proteins. Our goal in creating the mAb set 
for plasma profiling was to cover the natural, and im- 
portantly, accessible, epitopes with antibodies. Certainly, 
as the plasma proteome may contain up to 10 thousands 
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of proteins and obviously several-fold more epitopes, 
PlasmaScan 380TM covers only a small part of all avai- 
lable epitopes. However, considering that the low abun- 
dant protein species (<500 ng/ml) compartment of the 
human plasma is not accessible for profiling with this 
methodology, the epitope coverage of medium and highly 
abundant proteins (about 100 in total) is relatively higher. 
Nevertheless, the tool can already demonstrate the idea 
behind this type of experimentation: these antibodies are 
primarily planned to be used in experiments where no 
pre-conception is set toward antibody specificity and so 
these antibodies can serve as discovery tools capable of 
targeting high—as well as medium-abundant analytes in 
complex, fractionated or non-fractionated proteomes. 
The resolution of such proteome profiling efforts corre- 
late directly with the number of antibodies included and 
specificity becomes important if new discoveries have 
been made. Therefore the intended use of such a tool is 
to do the profiling experiment first, then characterize the 
selected target later using individual mAbs from the dis- 
covery tool. 
4.4. Experimental Strategy 
Based on the above, during the course of this study we 
first determined which of the antibodies recognize target 
proteins, the appearance of which was reproducibly dif- 
ferent in Caelyx sensitive vs. non-sensitive plasma. Be- 
ced substantial individ- 
tion of C activation by 
t made most “biological sense” is the decrease 
ctor 
H is bitor of C activation via the alternative 
ysfunc- 
tio
d β-sheet 
st
ith C3 levels in SLE 
[3
rect cleaving of C5 (substituting C3-de- 
pe
cause of the previously experien
ual and inter-experimental varia
Doxil in NHS in vitro, special attention was paid to re- 
producibility both in selecting a CSS and mAbs on the 
chips that tagged HSR-specific marker proteins. Thus, 
the extent of C activation by Caelyx in CSS was con- 
firmed in three independent experiments, as was the pro- 
filing of CSP versus Caelyx insensitive plasmas with the 
PS380 microarray. In the latter studies 8 antibodies 
showed differences which were consistent and statisti- 
cally significant in at least in two experiments out of 
three. In the following steps the cognate antigens (protein 
ID) of the antibodies were determined via immune-pre- 
cipitation followed by MS, WB or other biochemical ve- 
rification. 
4.5. Biomarker Candidates: Rationalizations 
of Findings 
With the above mentioned procedures eight potential 
biomarkers were identified. Among these, the protein 
change tha
of fH in CSP, which is in keeping with the known role of 
this coprotein in health and disease. FaC control gly
 a natural inhi
pathway, and, as shown in Figure 1(c), Caelyx activated 
C in CSS, at least in part, via the alternative pathway. 
Thus, at reduced fH levels one expects increased C acti-
vation by Caelyx via the alternative pathway. 
The primary function of fH in the body is the preven- 
tion of C activation on host cells by possessing both co- 
factor activity for Factor I-mediated C3b cleavage, and 
decay accelerating activity against the alternative path-
way C3-convertase, C3bBb. Consistent with its potential 
use as a HSR predictor, reduced fH levels or fH d
n were previously associated with radiocontrast reac- 
tions [26,27] and allergen-induced airway hyperrespon- 
siveness [28]. Because fH can be measured by commer- 
cial ELISA, it is a relatively easily accessible, realistic 
biomarker if further studies validate its use in predicting 
HSRs to Caelyx or other pseudo allergic drugs. 
As for the increase of SAP in CSP, SAP is a 25 kDa 
pentameric protein, member of the pentraxins family, a 
constituent of amyloid deposits causing amyloidoses. 
The latter diseases are characterized by the ordered agg- 
regation of normal globular proteins and peptides into 
insoluble fibers in various tissues. The flattene
ructure of SAP is similar to that found in lectins, which 
can mediate C activation, just as C-reactive protein 
(CRP), with which human SAP has 51% sequence ho-
mology. Based on these considerations it is possible that 
increased SAP may be a contributing factor to the in-
creased C activation by Caelyx in CSS. 
The rise of fibronectin in CSP may also reflect C acti- 
vation proactivity, inasmuch as fibronectin is one of the 
proteins that readily bind to liposomes exposed to plasma, 
and it is well known that the protein “corona” of lipo- 
somes [29] has a major impact on their properties and 
fate, including C activation [30]. 
Alpha-2-HS glycoprotein (A2HSG), also known as 
fetuin-A, is a Ca2+-binding plasma glycoprotein that is 
best known for its involvement in brain and bone tissue 
development [31]. Ca2+ is a known regulator of C activa-
tion, and, importantly, the serum level of A2HSG 
showed significant correlation w
2]. Nevertheless, this information is not sufficient to 
make hypotheses on why its increase in CSP would pro-
mote hypersensitivity to liposomes, just as the increases 
of fH or fHRP. 
As for the elevated prothrombin level in CSP, a com- 
plex crosstalk between the coagulation cascade and C- 
activation at different levels is well known [33,34], and 
was established specifically to radiocontrast-induced HSRs 
too [35]. In particular, thrombin is a potent anaphylatoxin 
generator via di
ndent C5 convertase) [36]; an effect that generated 
previously not documented intermediates of C5 C5(T) 
and C5b(T) [37]. The phenomenon is being considered as 
a new pathway of C activation [36]. In addition, throm-
bin also generates C3a when incubated with native C3 
[33], so it is possible that increased level of prothrombin 
Copyright © 2013 SciRes.                                                                                 ANP 
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promotes C activation as an extra thrombin reserve. In 
our study WB and ELISA clearly showed that our anti-
body specifically recognized prothrombin, yet the im-
mune-precipitates also contained large amounts of al-
pha-2 macroglobulin (A2M, Table 1). A2M is a general 
enzyme inhibitor that also inhibits, among others, C1 
[38]. It is therefore a further possibility that prothrombin 
interferes with inhibition of the activation of C via A2M, 
ultimately leading to increased activation.  
Regarding the elevation of C4 in CSP, although this 
protein is a key player in classical pathway C activation, 
its two-fold change may probably not be considered as a 
biomarker. This is because of the known variation of C4 
gene copy number in men, resulting in a wide range of 
C4 plasma protein concentrations among healthy subjects 
w
hould also be pointed out that the relation-
sh
 be useful in the prevention of a
lem affecting up to 10% of cancer
CSP and, if the proteins identified to date hold up in fur- 
The purpose of the report at this stage was to 
hi
 “NANOMEDI”). Further 
10/2/KONV-2010-0001 and 
knowledged, as well as the 
anomedici-
nes and Biologicals: Predictive Assays for Complement 
Mediated Infus Journal of Na- 
nomedicine, V -53. 
hich could cover an order of magnitude [39,40]. 
Likewise, it is difficult to attribute biological relevance 
to the demonstrated changes in apolipoprotein B, as it is 
a highly abundant protein, a key structural component of 
lipoproteins [41] whose level in blood shows much 
greater biological variation than the difference detected 
in our study. 
In summarizing the above facts and considerations, 
some of the protein changes in CSP are consistent with 
proneness for increased C activation, while others are 
difficult to fit in this paradigm, at least on the basis of our 
current knowledge on the function of these proteins. 
However, it s
ip between protein function and amount, estimated in 
our assay on the basis of epitope detection, is not strai- 
ghtforward. Our antibodies may recognize epitopes in-
volved in the function of proteins, as well as well as 
non-functional epitopes, and the functional epitopes de-
tected may represent neoepitopes associated with in-
creased or decreased function. Thus, at this time it cannot 
be a priori stated that a rise or decrease of a protein in our 
assay actually reflects increased or decreased function. 
5. Conclusions 
This study explores possible predictive biomarkers for 
Caelyx-induced HSRs, using a promising new method of 
biomarker identification. Without any pre-set conception 
we identified some potential markers, which, alone or in 
n combination, might
solved clinical prob
un- 
 
patients treated with Doxil or Caelyx, as well as thou- 
sands of other patients treated with pseudoallergy-cau- 
sing drugs, in whom CARPA is a life-danger or a barrier 
to therapy. 
The present work was conceived as a pilot, “feasibi- 
lity” study and not for providing clinical evidence for the 
use of any of the selected biomarkers. We realize the 
need for extending the tests to a large number of CSS/ 
ther analyses, their use will need to be validated in clini- 
cal studies. 
ghlight the complex methodical approach of biomarker 
identification for CARPA, its various steps and checks, 
whose communication at an early stage will hopefully 
help progress in this field. 
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